Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas
In the rapidly evolving landscape of urothelial cancer, Alicia Morgans and Petros Grivas discuss biomarker testing in patients in urothelial cancer with an emphasis on muscle-invasive and metastatic disease. Having an effect on the day to day treatment algorithms, Petros fields questions in the metastatic setting including who are the patients we are testing and how we are using the results.
Petros Grivas, MD Ph.D., Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle WA.
Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Watch: Erdafitinib in Bladder Cancer - Arjun Balar
INCB054828 for FGFR mutations or fusions (adjuvant setting): EudraCT 2017-004426-15
NCT03390504: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03410693: Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)
NCT02401542: A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy
NCT03834220: Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
NCT02459119: A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy
NCT02546661: An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY)
NCT03517956: Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)